Abstract
The value of lymph-node dissection in prostate cancer remains a subject of ongoing debate. To date, no study has provided conclusive evidence of a long-term oncological benefit. In this context, lymph-node dissection primarily serves a diagnostic purpose. The introduction of prostate-specific membrane antigen (PSMA) PET/CT imaging, characterized by its high sensitivity for detecting lymph-node metastases, increasingly approximates the diagnostic accuracy of pelvic lymph-node dissection (PLND). This technological advancement raises important ethical and clinical considerations regarding the necessity and justification of routinely performing an invasive procedure such as PLND in an era where high-quality, non-invasive imaging is readily available.
| Translated title of the contribution | Is performing a pelvic lymph-node dissection in prostate cancer still justified now that PSMA PET/CT is widely available? |
|---|---|
| Original language | Dutch |
| Journal | Tijdschrift voor urologie |
| Early online date | 2025 |
| DOIs | |
| Publication status | E-pub ahead of print - 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Lymph-node dissection
- Oncological outcome
- PSMA
- Prostate cancer
Fingerprint
Dive into the research topics of 'Is performing a pelvic lymph-node dissection in prostate cancer still justified now that PSMA PET/CT is widely available?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver